These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 34234349)

  • 1. Structure of human Ca
    Gao S; Yao X; Yan N
    Nature; 2021 Aug; 596(7870):143-147. PubMed ID: 34234349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Closed-state inactivation and pore-blocker modulation mechanisms of human Ca
    Dong Y; Gao Y; Xu S; Wang Y; Yu Z; Li Y; Li B; Yuan T; Yang B; Zhang XC; Jiang D; Huang Z; Zhao Y
    Cell Rep; 2021 Nov; 37(5):109931. PubMed ID: 34731621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ziconotide: can we use it in palliative care?
    Prommer EE
    Am J Hosp Palliat Care; 2005; 22(5):369-74. PubMed ID: 16225359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An integrated multiassay approach to the discovery of small-molecule N-type voltage-gated calcium channel antagonists.
    Finley MF; Lubin ML; Neeper MP; Beck E; Liu Y; Flores CM; Qin N
    Assay Drug Dev Technol; 2010 Dec; 8(6):685-94. PubMed ID: 21050074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ziconotide--a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain--a short review.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Oct; 44(10):478-83. PubMed ID: 17063978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analgesic (omega)-conotoxins CVIE and CVIF selectively and voltage-dependently block recombinant and native N-type calcium channels.
    Berecki G; Motin L; Haythornthwaite A; Vink S; Bansal P; Drinkwater R; Wang CI; Moretta M; Lewis RJ; Alewood PF; Christie MJ; Adams DJ
    Mol Pharmacol; 2010 Feb; 77(2):139-48. PubMed ID: 19892914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of arginine 10 to lysine substitution on ω-conotoxin CVIE and CVIF block of Cav2.2 channels.
    Berecki G; Daly NL; Huang YH; Vink S; Craik DJ; Alewood PF; Adams DJ
    Br J Pharmacol; 2014 Jul; 171(13):3313-27. PubMed ID: 24628243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ziconotide: a new option for refractory pain.
    Prommer E
    Drugs Today (Barc); 2006 Jun; 42(6):369-78. PubMed ID: 16845440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An orally available Ca
    Kutzsche J; Guzman GA; Willuweit A; Kletke O; Wollert E; Gering I; Jürgens D; Breitkreutz J; Stark H; Beck-Sickinger AG; Klöcker N; Hidalgo P; Willbold D
    Br J Pharmacol; 2024 Jun; 181(12):1734-1756. PubMed ID: 38157867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The alpha2delta auxiliary subunit reduces affinity of omega-conotoxins for recombinant N-type (Cav2.2) calcium channels.
    Mould J; Yasuda T; Schroeder CI; Beedle AM; Doering CJ; Zamponi GW; Adams DJ; Lewis RJ
    J Biol Chem; 2004 Aug; 279(33):34705-14. PubMed ID: 15166237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats.
    Wang YX; Gao D; Pettus M; Phillips C; Bowersox SS
    Pain; 2000 Feb; 84(2-3):271-81. PubMed ID: 10666532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ziconotide for treatment of severe chronic pain.
    Schmidtko A; Lötsch J; Freynhagen R; Geisslinger G
    Lancet; 2010 May; 375(9725):1569-77. PubMed ID: 20413151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structures of the R-type human Ca
    Yao X; Wang Y; Wang Z; Fan X; Wu D; Huang J; Mueller A; Gao S; Hu M; Robinson CV; Yu Y; Gao S; Yan N
    Nat Commun; 2022 Nov; 13(1):7358. PubMed ID: 36446785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elan: ziconotide review focused on off-label uses.
    Narayana AK
    Am J Hosp Palliat Care; 2005; 22(6):408. PubMed ID: 16323709
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular basis of toxicity of N-type calcium channel inhibitor MVIIA.
    Wang F; Yan Z; Liu Z; Wang S; Wu Q; Yu S; Ding J; Dai Q
    Neuropharmacology; 2016 Feb; 101():137-45. PubMed ID: 26344359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioactive Mimetics of Conotoxins and other Venom Peptides.
    Duggan PJ; Tuck KL
    Toxins (Basel); 2015 Oct; 7(10):4175-98. PubMed ID: 26501323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain.
    Wang YX; Pettus M; Gao D; Phillips C; Scott Bowersox S
    Pain; 2000 Feb; 84(2-3):151-8. PubMed ID: 10666519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of omega-conotoxin GVI A and MVIIC binding to Cav 2.1 and Cav 2.2 channels captured by anti-Ca2+ channel peptide antibodies.
    Ichida S; Abe J; Komoike K; Imanishi T; Wada T; Masuko T; Minami T
    Neurochem Res; 2005 Apr; 30(4):457-66. PubMed ID: 16076016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ca
    Scott MB; Kammermeier PJ
    Channels (Austin); 2017 Nov; 11(6):555-573. PubMed ID: 28837380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain.
    Atanassoff PG; Hartmannsgruber MW; Thrasher J; Wermeling D; Longton W; Gaeta R; Singh T; Mayo M; McGuire D; Luther RR
    Reg Anesth Pain Med; 2000; 25(3):274-8. PubMed ID: 10834782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.